US FDA conducts inspection at Alembic Pharmaceuticals' Oncology Formulation Facility

The United States Food and Drug Administration (US FDA) has conducted an inspection at Alembic Pharmaceuticals Limited's Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav from 28th February, 2024 to 8th March, 2024. The US FDA issued a Form 483 with four procedural observations.

The Company will provide comprehensive response to USFDA for the observations within the stipulated period.

The Company is committed to maintain the highest quality standards and compliance at all times.

Shares of Alembic Pharmaceuticals Limited was last trading in BSE at Rs. 998.90 as compared to the previous close of Rs. 999.25. The total number of shares traded during the day was 5418 in over 608 trades.

The stock hit an intraday high of Rs. 1019.05 and intraday low of 996.65. The net turnover during the day was Rs. 5440359.00.

Source : Equity Bulls

Keywords

AlembicPharmaceuticals INE901L01018 USFDAInspection Oncology Panelav